Product Images Imbruvica

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 15 images provide visual information about the product associated with Imbruvica NDC 57962-007 by Pharmacyclics Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It is a white to off-white solid with the empirical formula C25H24N6O2 and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water. The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure: - imbruvica 01

Figure 1 - imbruvica 02

This appears to be a graph or chart as it contains symbols such as percentages, months, and drugnames. It seems to be a comparison of two drugs - Imbruvica and Ofatumumab - based on their effectiveness after several months. Without further context or a visual of the graph/chart, it is difficult to ascertain what the data represents, what the symbols mean and how they are inter-related.*

Figure 2 - imbruvica 03

The text seems to be describing a comparison between two drugs: IMBRUVICA and ofatumumab. It might include data related to the effectiveness of these drugs over a period of 18 months, as well as the number of patients being treated. However, the text is not clear, and some characters are missing or incorrect.*

Figure 3 - imbruvica 04

This appears to be a graph showing the efficacy of a drug called IMBRUVICA compared to the drug chlorambucil over a period of 27 months. The y-axis represents the percentage of patients who were progression-free survival (PFS) and the x-axis represents the number of months. The graph displays a significant difference between the two drugs, as indicated by the p-value calculated. However, there is no information about what condition the drugs were being used to treat.*

Figure 4 - imbruvica 05

Figure 5 - imbruvica 06

Figure 6 - imbruvica 07

Figure 7 - imbruvica 08

PRINCIPAL DISPLAY PANEL - 28 Capsule Bottle Carton - imbruvica 09

PRINCIPAL DISPLAY PANEL - 28 Capsule Bottle Label - imbruvica 0a

Imbruvica (ibrutinib) is a medication provided in capsule form with 140mg dosage. Its indication, proper use, and precautionary measures are not available from the given text.*

PRINCIPAL DISPLAY PANEL – 90 Capsule Bottle LabelNDC 57962-140-09Imbruvica®(ibrutinib) capsules140 mgEach capsule contains: ibrutinib 140 mgSwallow capsules whole with water90 CapsulesRx OnlyPharmacyclics LLCAn AbbVie CompanyJanssen Biotech, Inc. - imbruvica 0b

PRINCIPAL DISPLAY PANEL – 120 Capsule Bottle LabelNDC 57962-140-12Imbruvica®(ibrutinib) capsules140 mgEach capsule contains: ibrutinib 140 mgSwallow capsules whole with water120 CapsulesRx OnlyPharmacyclics LLCAn AbbVie CompanyJanssen Biotech, Inc. - imbruvica 0c

PRINCIPAL DISPLAY PANEL - 90 Capsule Bottle Carton - imbruvica 0d

PRINCIPAL DISPLAY PANEL - 120 Capsule Bottle Carton - imbruvica 0e

PRINCIPAL DISPLAY PANEL - 28 Tablet Blister Carton - imbruvica 0f

Imbruvica* (ibrutinib) tablets are a medication used to treat certain types of cancer, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's Macroglobulinemia.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.